Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDX-1203
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MDX-1203 is an investigational antibody-drug conjugate (ADC) developed for the treatment of cancers such as renal cell carcinoma and non-Hodgkin’s lymphoma. It consists of a fully human monoclonal antibody targeting the extracellular domain of CD70, a protein overexpressed in certain malignancies, chemically linked to a prodrug form of a CC-1065 (rachelmycin) analogue via a stable peptide-based linker. The cytotoxic payload is a DNA minor groove-binding agent that forms covalent adducts with adenine bases in DNA, thereby preventing DNA replication and inducing cell death. MDX-1203 was designed to selectively deliver its cytotoxic payload to tumor cells expressing CD70[1][5][6]. Development has been discontinued[2].
- Other names
- anti-cd70 antibody-drug conjugate mdx-1203anti-cd-70 antibody-drug conjugate mdx-1203anti-cd 70 antibody-drug conjugate mdx-1203
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on MDX-1203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDX-1203.